- Home
- KGEI vs YMAB Comparison
KGEI vs YMAB Comparison
Compare KGEI & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KGEI
- YMAB
- Stock Information
- Founded
- KGEI 2008
- YMAB 2015
- Country
- KGEI United States
- YMAB United States
- Employees
- KGEI N/A
- YMAB N/A
- Industry
- KGEI
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- KGEI
- YMAB Health Care
- Exchange
- KGEI Nasdaq
- YMAB Nasdaq
- Market Cap
- KGEI 269.7M
- YMAB 270.5M
- IPO Year
- KGEI N/A
- YMAB 2018
- Fundamental
- Price
- KGEI $8.32
- YMAB $5.72
- Analyst Decision
- KGEI Strong Buy
- YMAB Strong Buy
- Analyst Count
- KGEI 1
- YMAB 10
- Target Price
- KGEI $11.00
- YMAB $21.10
- AVG Volume (30 Days)
- KGEI 149.5K
- YMAB 542.6K
- Earning Date
- KGEI 11-12-2024
- YMAB 03-04-2025
- Dividend Yield
- KGEI N/A
- YMAB N/A
- EPS Growth
- KGEI 2.07
- YMAB N/A
- EPS
- KGEI 0.48
- YMAB N/A
- Revenue
- KGEI $54,654,000.00
- YMAB $84,553,000.00
- Revenue This Year
- KGEI $15.83
- YMAB $6.41
- Revenue Next Year
- KGEI $26.54
- YMAB $18.15
- P/E Ratio
- KGEI $17.06
- YMAB N/A
- Revenue Growth
- KGEI 16.56
- YMAB N/A
- 52 Week Low
- KGEI $2.85
- YMAB $5.60
- 52 Week High
- KGEI $9.89
- YMAB $20.90
- Technical
- Relative Strength Index (RSI)
- KGEI 58.87
- YMAB 35.08
- Support Level
- KGEI $8.22
- YMAB $5.60
- Resistance Level
- KGEI $9.89
- YMAB $6.57
- Average True Range (ATR)
- KGEI 0.66
- YMAB 0.38
- MACD
- KGEI -0.01
- YMAB 0.10
- Stochastic Oscillator
- KGEI 45.67
- YMAB 11.43
About KGEI Kolibri Global Energy Inc. Common stock
Kolibri Global Energy Inc is a North American energy company focused on finding and exploiting energy projects in oil, gas, and clean and sustainable energy. It is focused on the acquisition, exploration, and production of oil and gas reserves. The company owns and operates shale oil and gas properties in the United States. Its segments include the United States, Canada and Others. The company derives a majority of its revenue from the United States.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.